Serum osteocalcin and vitamin D in postmenopausal diabetic azotemics.

K. C. Lu, S. D. Shieh, S. H. Chyr, S. H. Lin, B. L. Li, L. K. Diang, W. Q. Chen, Y. F. Lin

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

To clarify the role of serum vitamin D and bone remodeling markers in postmenopausal diabetic azotemics, we designed a study involving 3 different postmenopausal patient groups. Group I consisted of 20 diabetic women with renal insufficiency who were not yet on dialysis therapy. Group II consisted of 15 age-matched nondiabetic women with comparable degrees of renal insufficiency. Group III consisted of 20 age-matched women with normal renal function. We investigated the overnight fasting serum 25 (OH) vit-D, 1,25(OH)2 vit-D3, osteocalcin (OC), bone isoenzyme of alkaline phosphatase (ALK-PB) and intact parathyroid hormone (I-PTH) levels in these cases. The serum I-PTH and OC levels were statistically significantly higher, whereas 1,25(OH)2vit-D3 were significantly lower in Group I and Group II patients than in Group III patients. We found no significant correlation between elevation of I-PTH and reduced 1,25(OH)2 vit-D3 levels in Group I and Group II patients. I-PTH levels correlated positively with OC in Group I and Group II patients. There was no significant difference in serum 25(OH) vit-D among these 3 groups of patients. We conclude that (1) serum OC level may serve as a good parameter in evaluating secondary hyperparathyroidism in postmenopausal azotemics with or without diabetes, (2) even in the presence of menopause, renal failure per se is the main factor in determining serum 1,25(OH)2 vit-D3 levels in diabetic azotemics.

Original languageEnglish
Pages (from-to)97-104
Number of pages8
JournalDiabetes Research
Volume22
Issue number3
Publication statusPublished - 1993
Externally publishedYes

Fingerprint

Osteocalcin
Vitamin D
Parathyroid Hormone
Serum
Renal Insufficiency
Secondary Hyperparathyroidism
Bone Remodeling
Menopause
Type 2 Diabetes Mellitus
Isoenzymes
Alkaline Phosphatase
Dialysis
Fasting
Kidney
Bone and Bones

ASJC Scopus subject areas

  • Endocrinology
  • Endocrinology, Diabetes and Metabolism
  • Internal Medicine

Cite this

Lu, K. C., Shieh, S. D., Chyr, S. H., Lin, S. H., Li, B. L., Diang, L. K., ... Lin, Y. F. (1993). Serum osteocalcin and vitamin D in postmenopausal diabetic azotemics. Diabetes Research, 22(3), 97-104.

Serum osteocalcin and vitamin D in postmenopausal diabetic azotemics. / Lu, K. C.; Shieh, S. D.; Chyr, S. H.; Lin, S. H.; Li, B. L.; Diang, L. K.; Chen, W. Q.; Lin, Y. F.

In: Diabetes Research, Vol. 22, No. 3, 1993, p. 97-104.

Research output: Contribution to journalArticle

Lu, KC, Shieh, SD, Chyr, SH, Lin, SH, Li, BL, Diang, LK, Chen, WQ & Lin, YF 1993, 'Serum osteocalcin and vitamin D in postmenopausal diabetic azotemics.', Diabetes Research, vol. 22, no. 3, pp. 97-104.
Lu KC, Shieh SD, Chyr SH, Lin SH, Li BL, Diang LK et al. Serum osteocalcin and vitamin D in postmenopausal diabetic azotemics. Diabetes Research. 1993;22(3):97-104.
Lu, K. C. ; Shieh, S. D. ; Chyr, S. H. ; Lin, S. H. ; Li, B. L. ; Diang, L. K. ; Chen, W. Q. ; Lin, Y. F. / Serum osteocalcin and vitamin D in postmenopausal diabetic azotemics. In: Diabetes Research. 1993 ; Vol. 22, No. 3. pp. 97-104.
@article{39120a503a76439d8a591059ba8a5f4e,
title = "Serum osteocalcin and vitamin D in postmenopausal diabetic azotemics.",
abstract = "To clarify the role of serum vitamin D and bone remodeling markers in postmenopausal diabetic azotemics, we designed a study involving 3 different postmenopausal patient groups. Group I consisted of 20 diabetic women with renal insufficiency who were not yet on dialysis therapy. Group II consisted of 15 age-matched nondiabetic women with comparable degrees of renal insufficiency. Group III consisted of 20 age-matched women with normal renal function. We investigated the overnight fasting serum 25 (OH) vit-D, 1,25(OH)2 vit-D3, osteocalcin (OC), bone isoenzyme of alkaline phosphatase (ALK-PB) and intact parathyroid hormone (I-PTH) levels in these cases. The serum I-PTH and OC levels were statistically significantly higher, whereas 1,25(OH)2vit-D3 were significantly lower in Group I and Group II patients than in Group III patients. We found no significant correlation between elevation of I-PTH and reduced 1,25(OH)2 vit-D3 levels in Group I and Group II patients. I-PTH levels correlated positively with OC in Group I and Group II patients. There was no significant difference in serum 25(OH) vit-D among these 3 groups of patients. We conclude that (1) serum OC level may serve as a good parameter in evaluating secondary hyperparathyroidism in postmenopausal azotemics with or without diabetes, (2) even in the presence of menopause, renal failure per se is the main factor in determining serum 1,25(OH)2 vit-D3 levels in diabetic azotemics.",
author = "Lu, {K. C.} and Shieh, {S. D.} and Chyr, {S. H.} and Lin, {S. H.} and Li, {B. L.} and Diang, {L. K.} and Chen, {W. Q.} and Lin, {Y. F.}",
year = "1993",
language = "English",
volume = "22",
pages = "97--104",
journal = "Diabetes Research",
issn = "0265-5985",
number = "3",

}

TY - JOUR

T1 - Serum osteocalcin and vitamin D in postmenopausal diabetic azotemics.

AU - Lu, K. C.

AU - Shieh, S. D.

AU - Chyr, S. H.

AU - Lin, S. H.

AU - Li, B. L.

AU - Diang, L. K.

AU - Chen, W. Q.

AU - Lin, Y. F.

PY - 1993

Y1 - 1993

N2 - To clarify the role of serum vitamin D and bone remodeling markers in postmenopausal diabetic azotemics, we designed a study involving 3 different postmenopausal patient groups. Group I consisted of 20 diabetic women with renal insufficiency who were not yet on dialysis therapy. Group II consisted of 15 age-matched nondiabetic women with comparable degrees of renal insufficiency. Group III consisted of 20 age-matched women with normal renal function. We investigated the overnight fasting serum 25 (OH) vit-D, 1,25(OH)2 vit-D3, osteocalcin (OC), bone isoenzyme of alkaline phosphatase (ALK-PB) and intact parathyroid hormone (I-PTH) levels in these cases. The serum I-PTH and OC levels were statistically significantly higher, whereas 1,25(OH)2vit-D3 were significantly lower in Group I and Group II patients than in Group III patients. We found no significant correlation between elevation of I-PTH and reduced 1,25(OH)2 vit-D3 levels in Group I and Group II patients. I-PTH levels correlated positively with OC in Group I and Group II patients. There was no significant difference in serum 25(OH) vit-D among these 3 groups of patients. We conclude that (1) serum OC level may serve as a good parameter in evaluating secondary hyperparathyroidism in postmenopausal azotemics with or without diabetes, (2) even in the presence of menopause, renal failure per se is the main factor in determining serum 1,25(OH)2 vit-D3 levels in diabetic azotemics.

AB - To clarify the role of serum vitamin D and bone remodeling markers in postmenopausal diabetic azotemics, we designed a study involving 3 different postmenopausal patient groups. Group I consisted of 20 diabetic women with renal insufficiency who were not yet on dialysis therapy. Group II consisted of 15 age-matched nondiabetic women with comparable degrees of renal insufficiency. Group III consisted of 20 age-matched women with normal renal function. We investigated the overnight fasting serum 25 (OH) vit-D, 1,25(OH)2 vit-D3, osteocalcin (OC), bone isoenzyme of alkaline phosphatase (ALK-PB) and intact parathyroid hormone (I-PTH) levels in these cases. The serum I-PTH and OC levels were statistically significantly higher, whereas 1,25(OH)2vit-D3 were significantly lower in Group I and Group II patients than in Group III patients. We found no significant correlation between elevation of I-PTH and reduced 1,25(OH)2 vit-D3 levels in Group I and Group II patients. I-PTH levels correlated positively with OC in Group I and Group II patients. There was no significant difference in serum 25(OH) vit-D among these 3 groups of patients. We conclude that (1) serum OC level may serve as a good parameter in evaluating secondary hyperparathyroidism in postmenopausal azotemics with or without diabetes, (2) even in the presence of menopause, renal failure per se is the main factor in determining serum 1,25(OH)2 vit-D3 levels in diabetic azotemics.

UR - http://www.scopus.com/inward/record.url?scp=0027829219&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0027829219&partnerID=8YFLogxK

M3 - Article

C2 - 8076446

AN - SCOPUS:0027829219

VL - 22

SP - 97

EP - 104

JO - Diabetes Research

JF - Diabetes Research

SN - 0265-5985

IS - 3

ER -